Mark Opdam, The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the potential role of immunohistochemical (IHC) biomarkers in supporting chemotherapy de-escalation strategies for early breast cancer. Drawing from a biomarker analysis to the MATADOR trial (ISRCTN61893718), he highlights the established association between high stromal tumor-infiltrating lymphocytes (sTILs) and favorable outcomes in triple-negative breast cancer, alongside emerging signals that high EZH2 expression may also correlate with improved response to taxane-based regimens. While not yet ready for clinical application, these findings suggest that IHC-based tools could contribute to more personalized treatment strategies in the future. This interview took place at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
